CL2008002153A1 - Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r. - Google Patents
Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.Info
- Publication number
- CL2008002153A1 CL2008002153A1 CL2008002153A CL2008002153A CL2008002153A1 CL 2008002153 A1 CL2008002153 A1 CL 2008002153A1 CL 2008002153 A CL2008002153 A CL 2008002153A CL 2008002153 A CL2008002153 A CL 2008002153A CL 2008002153 A1 CL2008002153 A1 CL 2008002153A1
- Authority
- CL
- Chile
- Prior art keywords
- binding
- receptor
- treat
- pharmaceutical composition
- host cell
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108091008324 binding proteins Proteins 0.000 abstract 2
- 102000004557 Interleukin-18 Receptors Human genes 0.000 abstract 1
- 108010017537 Interleukin-18 Receptors Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95169207P | 2007-07-24 | 2007-07-24 | |
| US95169107P | 2007-07-24 | 2007-07-24 | |
| US7314208P | 2008-06-17 | 2008-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008002153A1 true CL2008002153A1 (es) | 2009-06-05 |
Family
ID=40282148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008002153A CL2008002153A1 (es) | 2007-07-24 | 2008-07-23 | Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8257707B2 (enExample) |
| EP (1) | EP2178917A4 (enExample) |
| JP (2) | JP2010534478A (enExample) |
| KR (1) | KR20100049535A (enExample) |
| CN (1) | CN101835489B (enExample) |
| AR (1) | AR067666A1 (enExample) |
| AU (1) | AU2008279127B2 (enExample) |
| BR (1) | BRPI0813016A2 (enExample) |
| CA (1) | CA2693503A1 (enExample) |
| CL (1) | CL2008002153A1 (enExample) |
| EA (1) | EA016783B1 (enExample) |
| IL (1) | IL202833A0 (enExample) |
| PE (1) | PE20090518A1 (enExample) |
| SG (1) | SG183070A1 (enExample) |
| TW (1) | TWI436778B (enExample) |
| WO (1) | WO2009015284A2 (enExample) |
| ZA (1) | ZA201001140B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| KR101603001B1 (ko) | 2010-08-25 | 2016-03-11 | 에프. 호프만-라 로슈 아게 | Il-18r1에 대한 항체 및 그의 용도 |
| KR20150016579A (ko) | 2012-05-30 | 2015-02-12 | 추가이 세이야쿠 가부시키가이샤 | 표적 조직 특이적 항원 결합 분자 |
| US8821242B2 (en) | 2012-07-25 | 2014-09-02 | Lumos Labs, Inc. | Systems and methods for enhancing cognition |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| KR102085179B1 (ko) * | 2013-05-07 | 2020-04-16 | 삼성전자주식회사 | 디바이스의 위치에 기초한 콘텐트 제공 시스템 및 방법 |
| EP3041863A4 (en) | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| CN111304752B (zh) | 2013-12-04 | 2024-12-31 | 中外制药株式会社 | 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库 |
| US10156562B2 (en) | 2014-05-16 | 2018-12-18 | Amgen Inc. | Assay for detecting Th1 and Th2 cell populations |
| AU2015305374B2 (en) | 2014-08-20 | 2019-08-22 | Covidien Lp | Systems and methods for spherical ablations |
| KR20160047889A (ko) * | 2014-10-23 | 2016-05-03 | 삼성전자주식회사 | 전자 장치 및 피공유자 추천 서비스 운용 방법 |
| AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| AU2019243848B2 (en) | 2018-03-26 | 2025-01-02 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| CA3104362A1 (en) * | 2018-06-19 | 2019-12-26 | Shanghaitech University | Human antibodies to human interleukin 18 receptor alpha and beta |
| ES2940311T3 (es) * | 2018-07-13 | 2023-05-05 | Alector Llc | Anticuerpos anti-sortilina y métodos de uso de los mismos |
| WO2020032230A1 (ja) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | 抗ｃｄ１３７抗原結合分子およびその使用 |
| EP4034556A1 (en) | 2019-09-26 | 2022-08-03 | Amgen Inc. | Methods of producing antibody compositions |
| EP4162257A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| KR20230087539A (ko) | 2020-10-15 | 2023-06-16 | 암젠 인크 | 항체 생산 방법에서의 상대적인 비결합 글리칸 |
| CN114736291B (zh) * | 2021-01-07 | 2023-08-11 | 中国科学院微生物研究所 | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 |
| EP4352094A1 (en) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| WO2023134767A1 (zh) * | 2022-01-14 | 2023-07-20 | 和径医药科技（上海）有限公司 | 一种靶向IL-18Rβ的抗体及其应用 |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776731A (en) * | 1996-02-21 | 1998-07-07 | Immunex Corporation | DNA encoding type-I interleukin-I receptor-like protein designated 2F1 |
| US7141393B2 (en) * | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| EP1049777B1 (en) * | 1998-01-23 | 2005-08-03 | Immunex Corporation | Acpl dna and polypeptides |
| WO1999037772A1 (en) * | 1998-01-23 | 1999-07-29 | Immunex Corporation | Il-18 receptors |
| BR9816013A (pt) * | 1998-09-01 | 2003-01-21 | Hayashibara Biochem Lab | Proteìna de ligação de interleucina-18 |
| IL131047A0 (en) | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
| AU7676300A (en) * | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
| EP2332579A3 (en) | 2000-02-10 | 2011-09-21 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| EP2281843B1 (en) * | 2000-06-16 | 2016-10-12 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| WO2002030984A1 (en) | 2000-10-13 | 2002-04-18 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| WO2002032374A2 (en) * | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| WO2002092008A2 (en) | 2001-05-16 | 2002-11-21 | Yeda Research And Development Co., Ltd. | Use of il-18 inhibitors for the treatement or prevention of sepsis |
| WO2003057821A2 (en) | 2001-10-26 | 2003-07-17 | Centocor, Inc. | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses |
| WO2003048328A2 (en) * | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| US20070025992A1 (en) * | 2003-07-18 | 2007-02-01 | Mochida Pharmaceutical Co., Ltd | Monoclonal antibody against platelet membrane glycoprotein VI |
| US7968684B2 (en) * | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| NZ553166A (en) * | 2004-07-16 | 2010-02-26 | Atsuo Sekiyama | IL-18 receptor antagonist and pharmaceutical composition containing the antagonist |
-
2008
- 2008-07-23 CL CL2008002153A patent/CL2008002153A1/es unknown
- 2008-07-24 AU AU2008279127A patent/AU2008279127B2/en not_active Ceased
- 2008-07-24 CA CA2693503A patent/CA2693503A1/en not_active Abandoned
- 2008-07-24 US US12/670,112 patent/US8257707B2/en not_active Expired - Fee Related
- 2008-07-24 EP EP08826644A patent/EP2178917A4/en not_active Withdrawn
- 2008-07-24 JP JP2010518389A patent/JP2010534478A/ja not_active Ceased
- 2008-07-24 BR BRPI0813016A patent/BRPI0813016A2/pt not_active IP Right Cessation
- 2008-07-24 KR KR1020107000286A patent/KR20100049535A/ko not_active Ceased
- 2008-07-24 WO PCT/US2008/071047 patent/WO2009015284A2/en not_active Ceased
- 2008-07-24 SG SG2012054557A patent/SG183070A1/en unknown
- 2008-07-24 CN CN2008800254509A patent/CN101835489B/zh not_active Expired - Fee Related
- 2008-07-24 EA EA201000238A patent/EA016783B1/ru not_active IP Right Cessation
- 2008-07-24 TW TW097128186A patent/TWI436778B/zh not_active IP Right Cessation
- 2008-07-24 AR ARP080103206A patent/AR067666A1/es not_active Application Discontinuation
- 2008-07-24 PE PE2008001261A patent/PE20090518A1/es not_active Application Discontinuation
-
2009
- 2009-12-20 IL IL202833A patent/IL202833A0/en unknown
-
2010
- 2010-02-17 ZA ZA2010/01140A patent/ZA201001140B/en unknown
-
2012
- 2012-08-20 US US13/589,984 patent/US8540993B2/en not_active Expired - Fee Related
-
2013
- 2013-09-03 US US14/017,014 patent/US20140093915A1/en not_active Abandoned
-
2014
- 2014-09-08 JP JP2014182029A patent/JP2015015957A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0813016A2 (pt) | 2015-12-15 |
| CN101835489A (zh) | 2010-09-15 |
| US8257707B2 (en) | 2012-09-04 |
| US20110014201A1 (en) | 2011-01-20 |
| EA016783B1 (ru) | 2012-07-30 |
| TWI436778B (zh) | 2014-05-11 |
| SG183070A1 (en) | 2012-08-30 |
| WO2009015284A3 (en) | 2009-10-01 |
| EP2178917A2 (en) | 2010-04-28 |
| ZA201001140B (en) | 2011-03-30 |
| AU2008279127B2 (en) | 2014-03-27 |
| WO2009015284A8 (en) | 2009-07-02 |
| CN101835489B (zh) | 2013-10-16 |
| AR067666A1 (es) | 2009-10-21 |
| US8540993B2 (en) | 2013-09-24 |
| US20140093915A1 (en) | 2014-04-03 |
| EA201000238A1 (ru) | 2010-08-30 |
| CA2693503A1 (en) | 2009-01-29 |
| JP2015015957A (ja) | 2015-01-29 |
| KR20100049535A (ko) | 2010-05-12 |
| EP2178917A4 (en) | 2012-03-28 |
| AU2008279127A1 (en) | 2009-01-29 |
| US20130034569A1 (en) | 2013-02-07 |
| JP2010534478A (ja) | 2010-11-11 |
| PE20090518A1 (es) | 2009-04-25 |
| TW200927167A (en) | 2009-07-01 |
| IL202833A0 (en) | 2011-08-01 |
| WO2009015284A2 (en) | 2009-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008002153A1 (es) | Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r. | |
| AR127516A2 (es) | VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN | |
| CY1123030T1 (el) | Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων | |
| CY1122399T1 (el) | Αγωνιστικοι παραγοντες δεσμευσης του υποδοχεα tnf | |
| CL2008002444A1 (es) | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. | |
| PE20121563A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
| BRPI1013688A8 (pt) | Proteínas de ligação de il-17. | |
| CL2012003196A1 (es) | Anticuerpo aislado o fragmento del mismo que se une específicamente a interleuquina-4 (il-4); molécula de ácido nucleico aislado que lo codifica y vector que la comprende; célula que comprende dicho vector; composición farmacéutica que comprende dicho anticuerpo; y su uso parar tratar una enfermedad alérgica, cáncer y asma. | |
| CL2012001096A1 (es) | Proteina de enlace a antigeno aislada que enlaza il-23, que comprende al menos tanto una region variable de cadena pesada como de cadena liviana que comprenden cdrs mutadas; acido nucleico, vector y celula hospedera que la codifican; composicion farmaceutica; y su uso para tratar enfermedades asociadas a il-23 en un paciente. | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| AR073072A1 (es) | Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| CL2009001001A1 (es) | Anticuerpo anti-factor d del complemento; polinucleotido codificante; vector que comprende dicho polinucleotido; celula huesped que comprende dicho vector; metodo de fabricacion del anticuerpo; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares. | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| ES2684475T3 (es) | Proteínas que se unen a beta amiloide | |
| CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
| BRPI1014016B8 (pt) | anticorpos humanizados para receptor tipo toll 2 e usos dos mesmos. | |
| CL2011001994A1 (es) | Anticuerpo antagonista que se une a la proteína ox40 humana; secuencia de adn que lo codifica; vector de clonación o de expresión que comprende dicho adn codificante; célula huésped que comprende dicho vector de clonación o expresión; proceso de producción de dicho anticuerpo; composición farmacéutica que comprende a dicho anticuerpo; uso médico de dicho anticuerpo; proteína de fusión que comprende a dicho anticuerpo. | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| AR079336A1 (es) | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| MX347954B (es) | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. | |
| CY1116288T1 (el) | Tnfsf απλης αλυσου μορια | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| DK1912674T3 (da) | Bispecifikt enkeltkæde FV-antistofmolekyle og fremgangsmåder til anvendelse deraf |